Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis

Bartosińska, Joanna; Zakrzewska, Ewelina; Król, Anna; Raczkiewicz, Dorota; Purkot, Joanna; Majdan, Maria; Krasowska, Dorota; Chodorowska, Grażyna; Giannopoulos, Krzysztof

doi:10.20452/pamw.4137

Cited by 13 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One possible explanation is the disease-specific roles of those co-signaling genes in autoimmune diseases. For instance, PD1 was differentially expressed on the CD4 + and CD8 + T cells between RA and psoriatic arthritis patients (90). Another possible explanation is the use of transcriptome data in whole blood or PBMC but not in specific types of immune cells.…”

Section: Discussionmentioning

confidence: 99%

Aberrant Expressions of Co-stimulatory and Co-inhibitory Molecules in Autoimmune Diseases

Wang

et al. 2019

Front. Immunol.

View full text Add to dashboard Cite

Co-signaling molecules include co-stimulatory and co-inhibitory molecules and play important roles in modulating immune responses. The roles of co-signaling molecules in autoimmune diseases have not been clearly defined. We assessed the expressions of co-stimulatory and co-inhibitory molecules in autoimmune diseases through a bioinformatics-based study. By using datasets of whole-genome transcriptome, the expressions of 54 co-stimulatory or co-inhibitory genes in common autoimmune diseases were analyzed using Robust rank aggregation (RRA) method. Nineteen array datasets and 6 RNA-seq datasets were included in the RRA discovery study and RRA validation study, respectively. Significant genes were further validated in several autoimmune diseases including Graves' disease (GD). RRA discovery study suggested that CD160 was the most significant gene aberrantly expressed in autoimmune diseases (Adjusted P = 5.9E-12), followed by CD58 (Adjusted P = 5.7E-06) and CD244 (Adjusted P = 9.5E-05). RRA validation study also identified CD160 as the most significant gene aberrantly expressed in autoimmune diseases (Adjusted P = 5.9E-09). We further found that the aberrant expression of CD160 was statistically significant in multiple autoimmune diseases including GD ( P < 0.05), and CD160 had a moderate role in diagnosing those autoimmune diseases. Flow cytometry confirmed that CD160 was differentially expressed on the surface of CD8 + T cells between GD patients and healthy controls ( P = 0.002), which proved the aberrant expression of CD160 in GD at the protein level. This study suggests that CD160 is the most significant co-signaling gene aberrantly expressed in autoimmune diseases. Treatment strategy targeting CD160-related pathway may be promising for the therapy of autoimmune diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Aberrant Expressions of Co-stimulatory and Co-inhibitory Molecules in Autoimmune Diseases

Wang

et al. 2019

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Shin et al evaluated blood Tfh cells in Korean patients with psoriasis and reached the same conclusion, and they added this T cell subset was not correlated with PASI scores (Shin et al, 2016). In patients with PsA, the percentages of CD4 + PD-1 + and CD8 + PD-1 + T cells were also significantly lower than that in healthy controls (Bartosińska et al, 2017). The reduction in PD-1 expression on T cells seems to be reasonable, since without the negative regulatory role of PD-1, the sustained activation of T cells will lead to chronic cytokine production to promote the development of psoriasis.…”

Section: Co-inhibitory Moleculesmentioning

confidence: 91%

The Role of Co-Signaling Molecules in Psoriasis and Their Implications for Targeted Treatment

Liu

Xu²,

Wu³

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Psoriasis is a chronic, systemic immune-mediated inflammatory disease manifesting in the skin, joint or both. Co-signaling molecules are essential for determining the magnitude of the T cell response to the antigen. According to the function of co-signaling molecules, they can be divided into co-stimulatory molecules and co-inhibitory molecules. The role of co-signaling molecules in psoriasis is recognized, mainly including the co-stimulatory molecules CD28, CD40, OX40, CD27, DR3, LFA-1, and LFA-3 and the co-inhibitory molecules CTLA-4, PD-1, and TIM-3. They impact the pathological process of psoriasis by modulating the immune strength of T cells, regulating the production of cytokines or the differentiation of Tregs. In recent years, immunotherapies targeting co-signaling molecules have made significant progress and shown broad application prospects in psoriasis. This review aims to outline the possible role of co-signaling molecules in the pathogenesis of psoriasis and their potential application for the treatment of psoriasis.

show abstract

“…Pathogenesis of the diseases remains only partially elucidated. Inflammatory mechanisms are closely associated with various immune disturbances [ 5 , 6 ], some of which affect such phenomena as control of apoptosis [ 7 ] or angiogenesis [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study

Kotulska¹,

Kucharz²,

Wiland³

et al. 2018

Reumatologia

Self Cite

View full text Add to dashboard Cite

ObjectivesBiologics are medications widely applied in the management of inflammatory rheumatic diseases. The drugs were found to be effective but their application is associated with some disadvantages. Medication with biologics is relatively expensive, and in Poland, it is carried out in specialized centers. The study was designed to evaluate various aspects of satisfaction and dissatisfaction of Polish patients treated with biologics.Material and methodsAn anonymous questionnaire was distributed in 23 Polish rheumatological centers involved in the treatment; 1212 returned questionnaires were used for analysis. Responses were received from 606 patients with rheumatoid arthritis, 427 with ankylosing spondylitis, 117 psoriatic arthritis, and 62 adult patients with juvenile idiopathic arthritis (in whom administration of the drugs had been introduced before they were 18 years old). The investigated group constituted about one-fifth of all rheumatic patients on biologics in Poland.ResultsA beneficial or very beneficial influence of the medication on the state of physical health was found mostly in patients with rheumatoid arthritis (51.3 and 30.5%) and ankylosing spondylitis (51.0 and 36.8%). Family life was improved by the treatment especially in patients with ankylosing spondylitis (40.7 and 35.6% beneficial and very beneficial, respectively), sleep quality and sexual life mostly in those with ankylosing spondylitis (beneficial/very beneficial influence 41.5/38.4, and 38.7/23.9, respectively). There was a rather small influence of biological treatment on the financial situation of the patients. In general, satisfaction with the treatment was evaluated as positive or very positive in 88% of all investigated patients.In a significant part of the patients, transportation to the medical center was considered as a disadvantage of the treatment. About one-third of the patients considered laboratory and imaging tests to be done before initiation of the medication as a difficulty, and for about 40% waiting time for qualification for the medication was a significant disadvantage. The route of drug administration was without importance for 4/5 of the patients.ConclusionsSumming up, the results were similar in the patients suffering from various diseases although those with psoriatic arthritis felt the highest satisfaction (possibly due to the positive aesthetic effect), and those with ankylosing spondylitis had significant improvement in sexual life (probably due to younger age). Relatively low satisfaction was found in patients with juvenile idiopathic arthritis. There was a small influence of medication on financial status of the patients. Application of biologics has few disadvantages and most of them are associated with the organization of health services (waiting time for the tests, transportation to the medical centers).

show abstract

Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis

Cited by 13 publications

References 17 publications

Aberrant Expressions of Co-stimulatory and Co-inhibitory Molecules in Autoimmune Diseases

Aberrant Expressions of Co-stimulatory and Co-inhibitory Molecules in Autoimmune Diseases

The Role of Co-Signaling Molecules in Psoriasis and Their Implications for Targeted Treatment

Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study

Contact Info

Product

Resources

About